Download PDF
Drug Res (Stuttg) 2015; 65(04): 199-204
DOI: 10.1055/s-0034-1375665
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Paclitaxel and Gemcitabine Combinational Drug-loaded Mucoadhesive Delivery System in the Treatment of Colon Cancers

X.-Y. Guo   *
1   Department of Gastroenterology, The Third Affiliated Hospital, College of Medicine, Xi’an Jiaotong University, Xi’an, China
,
P. Wang   *
1   Department of Gastroenterology, The Third Affiliated Hospital, College of Medicine, Xi’an Jiaotong University, Xi’an, China
,
Q.-G. Du
2   Department of General Surgery, The Third Affiliated Hospital, College of Medicine, Xi’an Jiaotong University, Xi’an, China
,
S. Han
3   State Key Laboratory of Cancer Biology & Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi’an, China
,
S.-M. Zhu
1   Department of Gastroenterology, The Third Affiliated Hospital, College of Medicine, Xi’an Jiaotong University, Xi’an, China
,
Y.-F. Lv
1   Department of Gastroenterology, The Third Affiliated Hospital, College of Medicine, Xi’an Jiaotong University, Xi’an, China
,
G.-S. Liu
1   Department of Gastroenterology, The Third Affiliated Hospital, College of Medicine, Xi’an Jiaotong University, Xi’an, China
,
Z.-M. Hao
4   Department of Gastroenterology, The First Affiliated Hospital, College of Medicine, Xi'an Jiaotong University, Xi’an, China
› Author Affiliations
Further Information

Publication History

received 10 April 2014

accepted 26 April 2014

Publication Date:
18 June 2014 (online)

Also available at
    Permissions and Reprints

Abstract

The combination of two different types of chemo­therapeutic drugs via nanocarriers is emerged as a promising strategy for treating multiple cancers. Such a co-delivery system will synchronize the drug exposure and synergize the therapeutic effects. Herein, we prepared a paclitaxel (PTX) and gemcitabine (GEM)-loaded N-succinyl chitosan nanoparticles (NSC NP) to target colon cancer. NSC NP showed a pH sensitive swelling at colonic pH and exhibited a sequential release pattern for both the drugs. Binary drug combination exhibited a synergistic cytotoxicity against HT-29 colon cancer cells with a remarkable G2/M phase arrest. Specifically, in vivo antitumor efficacy study showed that NSC NP prolonged the survival time of tumor-bearing mice up to 45 days wherein 50% of mice were still alive. Therefore, these results suggest that co-delivery of drugs with a suitable delivery system could potentially improve the therapeutic efficacy in colon cancers. The study can be further continued by using different types of chemotherapeutic drugs that targets different molecular targets using pH-sensitive nanocarriers.

Key words

combinational drug - pH sensitivity - nanoparticles - colon cancer - chemotherapeutic efficacy

* These authors contribute equally to this work.


 

  • References

  • 1 WHO Media Centre WHO Fact Sheet No. 297, Cancer 2012 http://www.who.int/mediacentre/factsheets/fs297/en/
    PubMed
  • 2 Chuah LH, Roberts CJ, Billa N et al. Cellular uptake and anticancer effects of mucoadhesive curcumin-containing chitosan nanoparticles. Colloids and Surfaces B: Biointerfaces 2014; 116: 228-236
    CrossrefPubMedGoogle Scholar
  • 3 Ma Y, Coombes AGA. Designing colon-specific delivery systems for anticancer drug-loaded nanoparticles: An evaluation of alginate carriers. J Biomed Mat Res Part A 2013;
    PubMedGoogle Scholar
  • 4 Rekha MR, Sharma CP. pH sensitive succinyl chitosan microparticles: a preliminary investigation towards oral insulin delivery. Trends Biomater Artif Organs 2008; 21: 107-115
    PubMedGoogle Scholar
  • 5 Yan C, Chen D, Gu J et al. Preparation of N-succinyl-chitosan and its physical-chemical properties as a novel excipient. Yakugaku Zasshi 2006; 126: 789-793
    CrossrefPubMedGoogle Scholar
  • 6 Jain RK, Stylianopoulos T. Delivering nanomedicines to solid tumors. Nat Rev Drug Discov 2010; 7: 653-664
    PubMedGoogle Scholar
  • 7 Acharya S, Sahoo SK. Sustained targeting of Bcr-Abl+leukemia cells by synergistic action of dual drug loaded nanoparticles and its implication for leukemia therapy. Biomaterials 2011; 32: 5643-5662
    CrossrefPubMedGoogle Scholar
  • 8 Hu JCM, Zhang L. Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem Pharmacol 2012; 83: 1104-1111
    CrossrefPubMedGoogle Scholar
  • 9 Lammers T, Subr V, Ulbrich K et al. Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers. Biomaterials 2009; 30: 3466-3475
    CrossrefPubMedGoogle Scholar
  • 10 Mura C, Nácherb A, Merinob V et al. Design, characterization and in vitro evaluation of 5-aminosalicylic acid loaded N-succinyl-chitosan microparticles for colon specific delivery. Colloids and Surfaces B: Biointerfaces 2012; 94: 199-205
    CrossrefPubMedGoogle Scholar
  • 11 Zhang L, Radovic-Moreno AF, Alexis F et al. Co-Delivery of Hydrophobic and Hydrophilic Drugs from Nanoparticle-Aptamer Bioconjugates. ChemMedChem 2007; 2: 1268-1271
    CrossrefPubMedGoogle Scholar
  • 12 Carrion C, de Madariaga MA, Domingo JC. In vitro cytotoxic study of immunoliposomal doxorubicin targeted to human CD34(+) leukemic cells. Life Sci 2004; 75: 313-328
    CrossrefPubMedGoogle Scholar
  • 13 Ji X, Gaoa Y, Chen L et al. Nanohybrid systems of non-ionic surfactant inserting liposomes loading paclitaxel for reversal of multidrug resistance. Int J Pharm 2012; 422: 390-397
    CrossrefPubMedGoogle Scholar
  • 14 Gabizon AA. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res 1992; 52: 891-896
    PubMedGoogle Scholar
  • 15 Saxena V, Hussain MD. Formulation and in vitro evaluation of 17-allyamino-17-demethoxygeldanamycin (17-AAG) loaded Polymeric mixed micelles for glioblastomamultiforme. Colloids and Surfaces B:Biointerfaces 2013; 112: 350-355
    PubMedGoogle Scholar